Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study by Högl, Birgit et al.
ORIGINAL COMMUNICATION
Progressive development of augmentation during long-term
treatment with levodopa in restless legs syndrome: results
of a prospective multi-center study
Birgit Ho ¨gl Æ Diego Garcı ´a-Borreguero Æ Ralf Kohnen Æ Luigi Ferini-Strambi Æ
Georgios Hadjigeorgiou Æ Magdolna Hornyak Æ Al de Weerd Æ Svenja Happe Æ
Karin Stiasny-Kolster Æ Viola Gschliesser Æ Renata Egatz Æ Birgit Frauscher Æ
Heike Benes Æ Claudia Trenkwalder Æ Wayne A. Hening Æ Richard P. Allen
Received: 29 December 2008/Revised: 29 July 2009/Accepted: 14 August 2009/Published online: 11 September 2009
 Springer-Verlag 2009
Abstract The European Restless Legs Syndrome (RLS)
Study Group performed the ﬁrst multi-center, long-term
study systematically evaluating RLS augmentation under
levodopa treatment. This prospective, open-label 6-month
study was conducted in six European countries and inclu-
ded 65 patients (85% treatment naive) with idiopathic RLS.
Levodopa was ﬂexibly up-titrated to a maximum dose of
600 mg/day. Presence of augmentation was diagnosed
independently by two international experts using estab-
lished criteria. In addition to the augmentation severity
rating scale (ASRS), changes in RLS severity (Interna-
tional RLS severity rating scale (IRLS), clinical global
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DOI 10.1007/s00415-009-5299-8impression (CGI)) were analyzed. Sixty patients provided
evaluable data, 35 completed the trial and 25 dropped out.
Augmentation occurred in 60% (36/60) of patients, causing
11.7% (7/60) to drop out. Median time to occurrence of
augmentation was 71 days. The mean maximum dose of
levodopa was 311 mg/day (SD: 105). Patients with aug-
mentation compared to those without were signiﬁcantly
more likely to be on higher doses of levodopa (C300 mg,
83 vs. 54%, P = 0.03) and to show less improvement of
symptom severity (IRLS, P = 0.039). Augmentation was
common with levodopa, but could be tolerated by most
patients during this 6-month trial. Patients should be
followed over longer periods to determine if dropout rates
increase with time.
Keywords Restless legs syndrome (RLS) 
Augmentation  Diagnosis  Rating scale  Clinical study
Introduction
Levodopa was the ﬁrst dopaminergic therapy investigated
forthetreatmentofrestlesslegssyndrome (RLS)[1,25]and
is licensed for the treatment of RLS in certain European
countries. Evidence for the efﬁcacy of levodopa was
demonstrated in the ﬁrst placebo-controlled short-term
clinical trials of dopaminergic treatment in RLS [6, 8, 9,
14, 20]. However, more than a decade ago augmentation of
RLS symptoms was noted as a serious complication of
levodopa therapy [2]. Augmentation is a worsening of RLS
symptom severity characterized by the occurrence of
RLS symptoms earlier in the day, by a shorter latency to
symptoms at rest, increased intensity of symptoms, and a
spreading of RLS symptoms to previously unaffected areas
of the body [3] compared to the status at start of treatment
or to favourable initial response. Trenkwalder et al. [21]
reported that 35% (8 of 23) of all treated patients during a
1 year open-label study of levodopa/benserazide therapy
discontinued the trial prematurely due to a time-shift
towards intolerable symptoms during the day. In a recent
double-blind, long-term (6 months) trial comparing the
dopamineagonistcabergolinetolevodopa/benserazide[23],
9.8% of patients treated with levodopa developed augmen-
tation requiring premature discontinuation. In summary, the
results of previous studies suggest a substantial risk for
augmentation with levodopa therapy. There has not, how-
ever, been any study speciﬁcally designed to prospectively
evaluate the development of augmentation with levodopa
treatment systematically by NIH criteria for augmentation
and with the augmentation severity rating scale (ASRS).
In the year 2003, the European RLS Study Group
(EURLSSG) decided to conduct an open-label study
with levodopa to validate an ASRS and to evaluate
prospectively and systematically the incidence and clinical
characteristics of augmentation [11]. In this manuscript, we
report the clinical outcome of this ﬁrst study designed to
evaluate RLS augmentation with levodopa treatment.
Methods
Design
This was a 6-month multi-center, open-label trial with a
ﬂexible dose of levodopa. The levodopa dose was adjusted
according to clinical needs and adverse effects. The inves-
tigators determined the optimal levodopa dose by means of
weekly contacts during the ﬁrst month (weeks 1 and 3 by
phone,andsitevisitsonweeks2and4).Patientsthenentered
the maintenance period of the study for a further 5 months
and were monitored with monthly site visits. During the
initial dose adjustment period, according to the protocol,
levodopa/benserazide had to be up-titrated from 100/25 mg
per day to a minimum dose of 200/50 mg per day, but could
be further increased to a maximum dose of 600/150 mg per
day, although this maximum dose was never reached during
the study. Dosage titration and adjustment were guided by
two principles: (a) the levodopa dose was to be increased
until elimination of all clinically meaningful symptoms, (b)
onceasufﬁcientdosagewasachieved,thatdosageshouldbe
kept as stable as possible over time. Dose adjustments were
permitted throughout the trial.
Patients
The study was designed to include patients who had never
before been treated with dopaminergic drugs (levodopa,
dopamine agonists), who were aged between 18 and
80 years and who met the diagnostic criteria for RLS as
established by the International RLS Study Group [3]. All
patients were judged by the investigators as severe enough
to require therapy for their RLS. Patients were excluded
from the study if RLS symptoms at baseline occurred
before 6 p.m. Further exclusion criteria included other
severe primary sleep disorders, neurological, psychiatric,
and pain disorders or severe medical and surgical condi-
tions, as well as clinically relevant laboratory abnormali-
ties. Concomitant therapy with any other psychotropic
medication which could have an inﬂuence on RLS symp-
toms (e.g., opioids, antiepileptics) was not permitted with
the exception of treatment with hypnotics, anxiolytic drugs,
antidepressants, benzodiazepines, and other therapies if the
treatment had been started at least 4 weeks prior to
enrollment into the study and the dose could be kept stable
throughout the trial. Domperidone could be administered in
the event of gastrointestinal complaints such as nausea.
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123Outcome measures
Severity of RLS symptoms was evaluated at all visits with
the International RLS severity scale (IRLS) [26], the RLS-
6 scales [15], and the clinical global impressions (CGI)
[16]. Severity of augmentation was assessed with the
ASRS [11]. The ASRS evaluates the severity of augmen-
tation by comparing the status before initiation of RLS
therapy to assessments during therapy. The ASRS is based
on an earlier onset of symptoms, prolonged latency to
symptoms at rest and spreading of symptoms to other body
parts. The severity of augmentation was graded from 0 to
24 (total score).
Other outcome measures were treatment satisfaction as
measured with the treatment satisfaction questionnaire for
medication (TSQM) [4], and quality of life (RLS quality of
life instrument (RLS-QLI) [5]). All rating scales were
assessed at baseline and then in monthly intervals or, in
case of dropouts, at the ﬁnal visit.
‘‘Gold standard’’ diagnosis of augmentation was based
on an expert rating. To obtain these expert ratings, data of
all patients were submitted to two highly experienced
experts in augmentation (Diego Garcia-Borreguero and
Richard P. Allen) asking for an independent assessment on
the presence (AUG) or absence of augmentation (N-AUG)
as based on published diagnostic criteria [3]. Experts dis-
cussed and resolved any divergent ratings so that the ﬁnal
diagnosis was a consensus diagnosis of both. Data provided
to the experts comprised the ASRS items, the IRLS and the
RLS-6 scores, the CGI ratings, and dosage of levodopa
from all visits of the study.
Statistical analyses
Efﬁcacy was analyzed in an exploratory manner for all
patients who had at least one post-baseline IRLS total score
(modiﬁed intention to treat set). Efﬁcacy analysis was
based on comparisons of changes between the baseline
visit and the patients’ individual ﬁnal visit using the IRLS
total score, the RLS-6 scales and the CGI. If patients
withdrew prematurely from the study, the last observation
was carried forward.
Patients were stratiﬁed according to occurrence of
augmentation as diagnosed by the independent experts.
Comparisons between AUG and N-AUG were performed
with two-sample tests for quantitative (Mann–Whitney U
test) or qualitative (Fisher’s exact test) variables. Time to
event data was described with a Kaplan–Meier statistic.
Sample size
The number of patients to be included in this trial was
based upon the requirements for assessing the validity of
the ASRS [11]. It was expected from earlier studies [2, 21]
that approximately half of all patients would experience
augmentation, thus 60 patients were planned to be included
in this trial.
Results
Centers and patients
Approval from the local ethics committees was achieved in
all of the eight participating centers in six European
countries. Between October 2003 and February 2005, 65
patients were enrolled into the trial. Two patients withdrew
their written consent to participate prior to any intake of
levodopa. Three other patients were withdrawn early after
baseline by the local investigators due to deviations from
the study protocol [no dose increase to 200 mg levodopa
possible (1 patient), previous treatment with dopamine
agonists (2 patients)]. Sixty RLS patients were ﬁnally
treated and evaluated. Of those, 25 patients (41.7%)
Table 1 Demographic and clinical characteristics of study patients
Statistics All patients
(N = 60)
With augmentation
(N = 36)
No augmentation
(N = 24)
P value
Age in years, M ± SD 52.6 ± 12.8 51.5 ± 12.0 53.3 ± 13.4 0.5373
Gender
Male, N (%) 22 (36.7) 10 (27.8) 12 (50.0) 0.0801
Female, N (%) 38 (63.3) 26 (72.2) 12 (50.0)
Body Mass Index (kg/m
2), M (SD) 25.4 (4.1) 25.1 (4.2) 25.8 (3.8) 0.5101
Diagnosis conﬁrmed by PSG, N (%) 25 (41.7) 14 (38.9) 11 (45.8) 0.7862
Familial history of RLS, N (%) 25 (41.7) 18 (50.0) 7 (29.2) 0.0892
Ferritin at baseline (lg/L), M ± SD (Md) 101 ± 70 (87) 82 ± 47 (77) 131 ± 88 (126) 0.0602
IRLS total score at baseline, (M ± SD) 24.7 ± 5.2 24.0 ± 4.0 25.7 ± 6.5 0.2533
P value associated with 2-sample tests (Mann–Whitney U test, Fisher’s exact test) to compare patients with or without augmentation
M arithmetic mean, SD standard deviation, N number of patients, Md Median, PSG polysomnography
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123discontinued the study prematurely. The most frequent
individual reasons for dropout were lack of efﬁcacy (n = 7
patients, 11.7% of all patients) and augmentation (n = 7,
11.7%). The other 11 patients discontinued due to adverse
events (n = 3, 5.0%), withdrawal of consent (n = 2, 3.3%)
or loss to follow-up (n = 6, 10%). Demographic and
clinical characteristics of the intention to treat population
(n = 60) are reported in Table 1, both for the total popu-
lation and stratiﬁed by occurrence of augmentation
according to the experts [yes (AUG): n = 36, no (N-AUG):
n = 24, see below]. Contrary to the study protocol, six
patients in two centers received prior dopaminergic therapy
(n = 3 levodopa, n = 4 dopamine agonists). Augmenta-
tion occurred in three of these patients (in 1 patient with
levodopa pre-treatment).
AUG and N-AUG differed in several of the baseline
characteristics: augmenters were more frequently females
and/or had a positive family history of RLS. They also
had a slightly lower serum ferritin measure at baseline,
although none of these differences reached signiﬁcance.
Augmenters had more frequently experienced lack of
efﬁcacy of at least one previous treatment therapy.
Previously treated and non-treated subgroups did not
differ in their levodopa dosage or in the response to
levodopa.
Treatment
On average, the patients were treated for approximately
4.5 months of the planned treatment duration of 6 months
with a mean levodopa dose of 311 mg/day (Table 2). There
was no difference in the average levodopa dose between
AUG and N-AUG (P = 0.2886, Mann–Whitney U Test).
There was a trend towards higher levodopa dose per kg
body weight in AUG that just missed our signiﬁcance
criteria (P = 0.0697, U test). In addition, the number of
patients who were treated with at least 300 mg levodopa
per day was higher in AUG (83.3%) than in N-AUG
(54.2%) (P = 0.0312, Fisher’s exact test, 2-sided).
Augmentation
After inspection of the original data of each patient, the two
independent experts classiﬁed 36 patients (60% of all
patients) to have deﬁnitely experienced augmentation
during levodopa treatment. Both groups differed in the
ASRS total score (P\0.0001): the mean and standard
deviations of the worst (maximum) total score (3 items,
range 0 to 24) were 7.4 ± 4.0 for AUG versus 2.0 ± 2.7 in
N-AUG. Regarding the range of the ASRS total score, the
mean ASRS total score indicates that in AUG the severity
Table 2 Levodopa treatment stratiﬁed by expert rating on augmentation
Statistics All patients
(N = 60)
With augmentation
(N = 36)
No augmentation
(N = 24)
P values
Duration of treatment (days)
M ± SD 140 ± 62 138 ± 60 143 ± 65 0.7632
Range 13–202 17–202 13–202
Maximum LD dose (mg)
M ± SD 311 ± 105 324 ± 98 292 ± 114 0.2886
Range 50–500 50–500 100–500
Maximum LD dose per kg body weight (mg/kg)
M ± SD 4.7 ± 1.7 5.0 ± 1.6 4.2 ± 1.8 0.0697
Range 1.39–8.40 2.35–8.40 1.39–8.00
Maximum LD dose (mg), N (%)
50 1 (1.7)
a 1 (2.8)
a 0
100 2 (3.3) 0 2 (8.3)
200 14 (23.2) 5 (13.9) 9 (37.5)
300 21 (35.0) 18 (50.0) 3 (12.5)
400 17 (28.3) 8 (22.2) 9 (37.5)
500 5 (8.3) 4 (11.1) 1 (4.2)
[200 43 (71.7) 30 (83.3) 13 (54.2) 0.0312
P value associated with 2-sample tests (Mann–Whitney U test, Fisher’s exact test) to compare patients with or without augmentation
M arithmetic mean, SD standard deviation, Range minimum–maximum, LD levodopa
a One patient who did not tolerate 100 mg L-Dopa, early discontinuation
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123of augmentation was, on average, in the lower range of the
scale.
In Fig. 1, time to occurrence of augmentation is pre-
sented as a Kaplan–Meier plot from a life-table analysis.
The date of onset of augmentation was deﬁned by the
independent experts. Median time to augmentation was
71 days with a range between 18 and 182 days. Figure 1
illustrates that augmentation can occur at any time within
6 months of start of therapy. Figure 2 illustrates the change
over time of augmentation severity, levodopa dose, and
RLS severity according to the IRLS total score during the
course of the study. In this ﬁgure, we carried forward
available data for days between visits until a measure
changed or until the end of the study in patients who
discontinued the trial prematurely (LOCF). While the total
scores on the augmentation-speciﬁc rating scale ASRS
increased progressively over time, the IRLS total score and
the levodopa dose remained stable during maintenance
treatment, indicating that treatment efﬁcacy was main-
tained on average. The ﬁgure suggests that the process of
augmentation contains speciﬁc features that are not
reﬂected in severity scales, and that it might be different
from pharmacological tolerance.
Clinical outcome
Table 3 summarizes baseline-endpoint comparisons for the
scale measures of severity of RLS, quality of life, and
satisfaction with treatment based on LOCF. In general,
improvements (as based on IRLS or CGI) were larger in
N-AUG than in AUG. In the RLS-6 scales, however, only
severity at bedtime was signiﬁcantly more improved in
N-AUG (P = 0.018), but quality of sleep and daytime
tiredness showed similar changes across groups. In the
TSQM, effectiveness of and global satisfaction with levo-
dopa therapy were rated more favorably in N-AUG than in
AUG.
Safety
Safety monitoring was performed at each visit with a focus
on established side effects of levodopa/benserazide
requiring intervention. Three patients discontinued the
study prematurely due to adverse events, two augmenters
(subjectively reported impaired cognitive ability in one
patient, impaired coordination and emotional disturbance
in the other), and one patient without augmentation due to
tiredness during the day, nausea and nightmares.
Discussion
This prospective, open-label, multi-center study conﬁrms
the high risk for augmentation during levodopa therapy of
RLS patients. Augmentation was diagnosed in 60% of all
analyzable patients and occurred at all doses of levodopa
between 50 and 500 mg/day. Furthermore, augmentation
could occur at any time during the 6 month treatment
period and its prevalence increased progressively with time
(Fig. 1). In addition, its severity also increased with the
duration of levodopa therapy (Fig. 2).
A relationship between the incidence of augmentation
and higher levodopa dosages is supported by higher rates
of augmenters than non-augmenters who were treated with
300 mg per day or higher when augmentation occurred. In
addition, we found a marginally positive correlation
between levodopa dose and augmentation when the
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Fig. 1 This ﬁgure shows a Kaplan–Meier survival curve on the
occurrence of augmentation according to expert rating throughout the
progress of the trial (treatment days on X-axis). The ﬁrst assessment
of the ASRS was performed on day 29. Patients with no augmentation
are censored with the date of their last observation within the study
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Fig. 2 IRLS (green line): original values, levodopa dose (black line)
9 0.1. ASRS total score (red line) 9 10 to achieve comparable scale
level for all three variables. Values were carried forward for all
patients until a change in either variable occurred. In dropouts, the last
observed value was carried forward for all three variables
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123absolute dose was related to the patients’ body weight.
However, we cannot make a valid statement on the
robustness of this relationship due to a large heterogeneity
of treatment strategies in the participating centres.
Although 70% of the patients treated with doses higher
than 200 mg developed augmentation, the remaining 30%
included some who tolerated even higher doses without
any indication that increased doses above 300 mg further
increased the risk of augmentation. We do not know
whether those with no augmentation despite high doses of
levodopa would also have become augmenters with addi-
tional time on the same doses.
Within the 6-month treatment period, 7 out of 36
patients (19.4%) with augmentation or 11.7% of the total
population had to discontinue treatment due to augmenta-
tion. This ﬁnding is similar to a discontinuation rate of
9.8% under levodopa/benserazide in the comparison trial
with cabergoline [23] over 6 months and signiﬁcantly
higher than under cabergoline (4.0%). The overall results
of the ASRS in our trial show that severity of augmentation
was in the lower range of the scale in the majority of all
affected patients. This ﬁnding reﬂects the outcome of our
study, unreported until now, that 29/36 (80.6%) of patients
with augmentation have tolerated this worsening of their
disorder, e.g., if symptoms occur earlier than usual or
during the day at rest. This ﬁnding underscores the point
that augmentation has varying degrees of severity, and in
many cases might be tolerable or compensated for.
Therefore, a criterion to distinguish tolerable from clini-
cally relevant augmentation is necessary as deﬁned in
the new guidelines on augmentation [12]. First clinical
recommendations on how to treat the varying degrees of
augmentation have been proposed [13]. Further studies
should address whether the severity of augmentation
increases or varies over time, as it does not seem to be a
stationary process but in general appears to become more
common with longer duration of treatment.
This study also shows that patients who develop aug-
mentation have a less favorable treatment outcome com-
pared to those who do not develop augmentation. Clinically
relevant response to levodopa treatment was more pro-
nounced in patients without augmentation than in aug-
menters, as shown by larger improvements of the IRLS
total score, the RLS-6 scales, the CGI and the patients’
assessment of the treatment’s effectiveness and their global
satisfaction with the levodopa therapy.
Table 3 Comparisons of patients with or without augmentation in clinical outcome scores (change from baseline to individual last visit during
treatment phase)
Scale Subscale Baseline Change from baseline P value
 
All patients With augmentation No augmentation
IRLS Total score 24.7 ± 5.2 -6.4 ± 11.2 -12.4 ± 10.7 0.039
CGI 1. Severity 4.5 ± 0.8 -0.7 ± 1.8 -1.9 ± 1.6 0.036
2. Change in condition
a n.a. 3.0 ± 1.9 1.8 ± 1.2 0.004
3. Therapeutic effect
a n.a. 2.4 ± 1.3 1.5 ± 0.9 0.005
4. Side effects
a n.a. 1.7 ± 0.9 1.4 ± 0.6 0.265
RLS-6 Severity bedtime 5.7 ± 3.0 -2.3 ± 4.2 -4.8 ± 3.0 0.018
Severity at night 5.1 ± 2.9 -1.7 ± 3.8 -3.4 ± 3.3 0.101
Severity day at rest 4.0 ± 2.9 0.3 ± 3.8 -1.6 ± 3.1 0.060
Severity day active 1.2 ± 1.7 -0.2 ± 2.0 -0.6 ± 1.6 0.301
Sleep quality 6.7 ± 1.9 -2.3 ± 3.7 -3.0 ± 3.1 0.346
Daytime tiredness 4.7 ± 3.1 -0.9 ± 3.9 -2.3 ± 3.6 0.142
QLI Social function 66.5 ± 24.5 ?8.6 ± 24.7 ?22.2 ± 25.7 0.053
Daily function 71.3 ± 12.8 ?6.8 ± 19.9 ?5.6 ± 24.5 0.984
Sleep quality 34.8 ± 18.2 ?15.3 ± 27.2 ?27.3 ± 28.4 0.189
Emotional wellbeing 57.1 ± 30.9 ?10.0 ± 37.5 ?23.2 ± 34.0 0.168
TSQM Effectiveness
a n.a. 57.6 ± 27.5 71.5 ± 31.4 0.049
Side effects
a n.a. 56.3 ± 29.2 60.6 ± 32.6 0.463
Convenience
a n.a. 79.6 ± 16.7 86.5 ± 16.4 0.076
Global satisfaction
a n.a. 50.6 ± 32.9 75.8 ± 30.1 0.003
IRLS, CGI item 1, RLS-6: negative signs indicate improvement; CGI 2 to 4: score 1 = best condition; QLI positive signs indicate improvement;
TSQM 100 = best condition
  P values associated with the Mann–Whitney U test
a No baseline values are available for these scales, they represent ratings of change
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123In the literature, several sometimes contradictory risk
factors for augmentation have been suggested to date: type
of drug (higher under levodopa than under dopamine
agonists), higher doses of drugs, duration of treatment,
previous augmentation or tolerance, severity of RLS at start
of therapy, familial RLS, secondary RLS and lack of
neuropathy [18, 22, 24]. However, such associations are
either controversial or controlled data are lacking [12]. The
sample size in our study was too small for multivariate
regression analyses; however, longer duration of treatment,
higher dose, longer duration of symptoms, and any previ-
ous RLS treatment were found more frequently in AUGs
than in N-AUGs treated with levodopa. In addition, low
serum ferritin level has been found in two independent
previous studies to be a risk factor for augmentation
[10, 24] and the association was marginally signiﬁcant
in our study. Considering that some patients treated with
high dosages of levodopa ([300 mg) for 6 months did
not experience augmentation, future research might iden-
tify protective factors for augmentation, e.g., a genetic
disposition.
Besides the description of a progressive development of
augmentation associated with duration of treatment during
long-term levodopa therapy, a main contribution of this
trial to augmentation research is the identiﬁcation of
tolerable and intolerable severity of this treatment com-
plication: augmentation with ASRS total severity scores in
the lower range of the scale might be tolerated by many
affected patients assuming it does not become progres-
sively worse with longer treatment duration. Similar
experiences have been reported from trials with dopamine
agonists [7, 17, 19]. The recent revision of the criteria for
augmentation [12] proposed conditions for clinically rele-
vant augmentation, such as the need for the patients to
change therapy or to adjust their daily activities. In light of
this new concept of augmentation, the clinical relevance
of most previous reports on augmentation might need to
be re-assessed since they were based on a dichotomized
concept of augmentation (presence or absence) and used a
variety of different deﬁnitions and criteria. Augmentation
rates as reported in the literature for dopamine agonists
were: pergolide 15–27%; pramipexole 8–56%, cabergoline
3–9%, compared to levodopa 10–72% (for an overview see
Garcia-Borreguero et al. [13]). In particular, the dosage
level of levodopa has to be controlled in such re-analyses
of previous data. It is also important to realize that we have
hardly any data on very long durations of treatment (e.g.,
10 years), so at this point we do not know the extent
to which augmentation may or may not gradually worsen
with duration of treatment. Obtaining these data should be
critical for considering future treatment options, including
whether or not early detection of mild augmentation has
any clinical relevance for preventing development of more
serious clinically signiﬁcant augmentation.
From a clinical point of view, our study suggests that
any clinician who prescribes levodopa to RLS patients
should be aware of the potential occurrence of augmenta-
tion at any time and any dose during treatment. In accor-
dance with recommendations on prevention of
augmentation [13], levodopa should be applied to RLS
treatment at maximum dosages of 200 mg/day or 3 mg/kg
body weight. We suggest that a careful ongoing review of
patients on levodopa therapy is warranted and that patient
education should include an explanation about the possi-
bility and nature of augmentation.
This study was designed in 2003 as one of the ﬁrst
prospective multicenter trials on drug-induced augmenta-
tion (see also Trenkwalder et al. [23]). The intention of the
authors was to administer levodopa close to routine prac-
tice. Therefore, the selection criteria for study patients were
broad and protocol deviations such as previous therapy
with dopaminergic drugs were tolerated. In 2004, what is
nowadays common knowledge in RLS treatment was still
unknown, such as the increased risk of augmentation under
high dosages of levodopa or the inﬂuence of concomitant
medication such as antidepressants on onset or aggravation
of RLS symptoms. On the other hand, our current knowl-
edge on levodopa-induced augmentation was supported
substantially by the results of this trial as indicated by the
recommendation to limit the maximum dosage of levodopa
to a very low level of 200 mg/day. We also introduced the
concept of diagnosis of augmentation by use of an expert
board instead of individual investigators to achieve as
much standardized evaluation of the study data as possible.
This approach is currently state of the art in augmentation
research.
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